A randomized and comparative study of ipragliflozin and sitagliptin in patients with type 2 diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Jun 2017 Results (n=66) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan record.